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Introduction
Allogeneic stem cell transplant (allo-SCT) has the potential to 
provide curative therapy for patients with high-risk acute leuke-
mia, lymphoid malignancies, and other malignant diseases (1–3). 
Despite improvements in HLA typing and stem cell donor selec-
tion, graft-versus-host disease (GVHD) remains the major compli-
cation of allo-SCT, with incidence of acute GVHD (aGVHD) rang-
ing from 30% to 80% and accounting for 15%–30% of mortality 
of transplant recipients (4, 5). Grade III–IV aGVHD involving the 
lower gastrointestinal tract is the most common cause of morbid-
ity and mortality from aGVHD. The administration of corticoste-
roids is the standard approach for the treatment of patients with 
grade II–IV aGVHD, with approximately 70% of patients treated 
responding (6). However, the long-term survival of patients with 
corticosteroid-nonresponsive aGVHD involving the lower GI tract 
is dismal, with less than 20% of those patients alive 1 year after 
diagnosis (7). Clearly, new forms of therapy are needed for the 
treatment of patients with corticosteroid-nonresponsive aGVHD 
of the lower GI tract.
Research over the past 40 years has primarily focused on the 
role of donor-derived T cells in the pathogenesis of aGVHD (8). 
Work from both preclinical transplant models and clinical trans-
plant studies has indicated a critical role for T cells, specifically 
Th1/Tc1 T cells, in the pathophysiology of aGVHD. Thus, treat-
ment of aGVHD has almost entirely focused on targeting donor T 
cells. However, despite highly potent therapy targeting T cells such 
as alemtuzumab, outcome for patients with corticosteroid-nonre-
sponsive aGVHD has not improved (7). This has led to increasing 
interest in the role of other proinflammatory immune cells, such 
as macrophages, neutrophils, and B lymphocytes, in the patho-
physiology of aGVHD, and the local function of antiinflammatory 
immune and non-immune cells (9, 10).
A second group of immune cells that diminish the effector 
function of proinflammatory immune cells may be critical to the 
immune response during aGVHD. FoxP3-expressing Tregs lim-
it the expansion and effector function of donor T cells. Infusion 
of donor Tregs has been shown to be an effective prophylactic 
approach for the prevention of aGVHD (11). At this time, it is not 
clear whether the infusion of Tregs can effectively treat ongoing 
aGVHD. Our group has shown that IL-13–activated bone mar-
row myeloid-derived suppressor cells (MDSCs) used at the time 
of bone marrow transplant (BMT) in preclinical models inhibited 
GVHD lethality (12). However, their ability to treat active aGVHD 
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decreased numbers of circulating CD69+ ILC2s and ILC3s had an 
increased risk of aGVHD (22).
We hypothesized that unlike ILC3s, there was a population 
of innate lymphoid cells that was sensitive to conditioning thera-
py. Here, we demonstrate that ILC2s in the GI tract but not in the 
lung are highly sensitive to conditioning therapy prior to allo-SCT 
and, more importantly, that there is a quite limited repopulation of 
ILC2s in the GI tract from donor bone marrow. Infusion of IL-33–
activated donor ILC2s significantly reduced GI tract–associated 
aGVHD mortality, improving GVHD scores and associated weight 
loss in two separate murine models. Additionally, ILC2 treatment 
of recipients with established aGVHD significantly increased 
survival. Finally, we provide a previously unreported mechanism 
by which ILC2s recruit donor myeloid-derived suppressor cells 
(MDSCs) to the lower GI tract to mitigate aGVHD. These studies 
strongly suggest that expanded ILC2s may be a potent cellular 
therapy for the treatment of lower GI tract aGVHD.
Results
Type 2 innate lymphoid cells are radiation sensitive. To evaluate the 
effect of conditioning therapy on ILCs, we irradiated B6D2 mice 
is quite modest. Thus, despite intense research evaluating the 
function of immune cells that diminish effector T cell function, 
there is not a currently identified population of cells that has sig-
nificant activity treating active aGVHD.
Over the past decade, a number of researchers have identified 
populations of innate immune cells (ILCs) critical for rapid muco-
sal immune responses (13, 14). The initial ILC described 4 decades 
ago was the NK cell. Recently, multiple populations of ILCs that 
generate IFN-γ (ILC1), IL-5 and IL-13 (ILC2), and IL-17 and/or 
IL-22 (different subpopulations of ILC3s) have been described 
(15). Like Th2 cells, ILC2s — previously termed nuocytes or innate 
helper type 2 cells — express GATA-3 and ID-2. They generate sub-
stantial type 2 cytokines. ILC2s, which respond to IL-25, are criti-
cal to the anti-helminth immune response and play an important 
role in allergen-induced inflammation (16–20). The role of innate 
cells in the biology of aGVHD has been evaluated recently. Hanash 
et al. demonstrated that ILC3s in the GI tract were not sensitive 
to conditioning therapy but were decreased in mice with acute 
GVHD. The loss of ILC3s was associated with decreased genera-
tion of IL-22, impaired epithelial barrier function, and diminished 
numbers of intestinal stem cells (21). In humans, patients with 
Figure 1. ILC2s are sensitive to radiation and chemotherapy conditioning. (A) Flow cytometry gating scheme used to define ILC2 and ILC3 subsets in 
MLN. (B) Quantitation by flow cytometry of innate lymphoid and CD4+ T cells in the LP, MLN, or lung in mice without irradiation (filled circles) or 24 hours 
after receiving radiation (950 cGy) (open circles). Results represent 3 independent experiments; n = 5 for each group. (C) Quantitation of ILC2s in the LP and 
MLN in mice receiving no therapy (filled circles) or 24 hours after receiving 200 mg/kg of cyclophosphamide (open circles). Results represent 2 independent 
experiments; n = 4 for each. (D) Quantitation of host and donor-derived ILC2s in the LP and lung 28 days after BMT; mean ± SEM. Results represent 2 
independent experiments; n = 5. Statistical analysis by Student’s t test with Welch’s correction, ***P < 0.001, **P < 0.01, *P < 0.05.
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Thus, ILC2s in the GI tract, but not the lung, are sensitive to condi-
tioning therapy and have extremely limited repopulation kinetics 
from donor bone marrow in the first 4 weeks after transplant.
Co-infusion of ILC2s reduces aGVHD and increases recipient 
survival. To evaluate the function of ex vivo ILC2s in GVHD biol-
ogy, we expanded murine ILC2s as previously described (24) and 
verified their phenotype by flow cytometry (Supplemental Figure 
2, A–C) and transcriptome analysis (Supplemental Figure 3, A and 
B, and Supplemental Table 1). Next, we performed survival stud-
ies in a murine model of allo-SCT with co-infused ILC2s. Splenic 
donor C57BL/6 (B6) T cells with a 1:1 ratio of ILC2s (BM, T cells 
+ WT ILC2) or without ILC2s (BM + T cells) were infused into 
lethally irradiated haploidentical recipients on day 0. Co-trans-
plantation of a single dose of ILC2s significantly improved sur-
vival, with 70% of recipients surviving 60 days after transplant 
(Figure 2A). There was a significant reduction in both the clinical 
score and weight loss in mice receiving ILC2s (Figure 2, B and C). 
On day 20, there was a decrease in pathology score in the colon 
and spleen (Figure 2D), with a nonsignificant decrease in the ile-
um and no difference in the lung and liver (Supplemental Figure 
4A). Using a 2:1 ratio of ILC2s to T cells, we repeated the survival 
studies in a B6-into-BALB/c transplant model. There was a sig-
(see Methods) and quantitated GI tract ILCs. ILC3s in the lami-
na propria (LP) of the colon but not the mesenteric lymph node 
(MLN), isolated 24 hours after lethal irradiation, were relatively 
resistant to radiation (Figure 1, A and B) (13, 21, 23). In contrast, 
CD4+ T cells in the LP and lung were radiation sensitive. Unlike 
ILC3s, ILC2s from the LP of the colon were highly sensitive to 
radiation (Figure 1B). Similar to ILC3s, ILC2s in the MLN and 
spleen were exquisitely sensitive to radiation (Figure 1B and Sup-
plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI91816DS1). Interesting-
ly, lung ILC2s were relatively resistant to radiation therapy (Fig-
ure 1B). We also examined the effects of chemotherapy on ILC2s 
and found that they were significantly reduced within 24 hours of 
cyclophosphamide treatment in the LP and MLN (Figure 1C).
Next, we evaluated the reconstitution of murine donor and 
recipient ILC2s 4 weeks after allo-SCT. Over this time period, 
there were extremely limited numbers of donor and/or recipient 
ILC2s in the LP of recipient mice that received irradiation and 
bone marrow without donor T cells, with a decrease in ILC2s in 
the LP at day 28 compared with day 1 (Figure 1D). By comparison, 
there were approximately 20-fold greater numbers of donor and/
or host ILC2s in the lung on day 28 after transplant (Figure 1D). 
Figure 2. Co-transplantation of donor ILC2s reduces aGVHD incidence. Lethally irradiated B6D2 mice received TCD BM (BM only), BM plus total splenic T 
cells (BM + T cells), or BM plus T cells with activated ILC2s (BM, T cells + WT ILC2). (A) Kaplan-Meier plot of survival following allo-SCT; 1 representative of 
3 experiments shown (n = 8 each experiment). Log-rank (Mantel-Cox) test, ***P < 0.001. (B) Clinical score and (C) percentage of body weight change after 
transplantation. Two-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons, ***P < 0.001. (D) Pathology scores of histo-
logical evaluations of GVHD target organs, 20 days after BMT (n = 4 mice per group). Student’s t test with Welch’s correction, *P < 0.05. (E) Kaplan-Meier 
plot for irradiated BALB/c mice that received TCD BM (BM only), BM plus splenic T cells (BM + T cells), or BM plus T cells with ILC2s (BM, T cells + WT ILC2). 
Results represent 2 independent experiments; n = 14. Log-rank (Mantel-Cox) test, ***P < 0.001. (F) Kaplan-Meier plot for B6D2 recipients that received BM 
alone (BM only), BM and splenic T cells (BM + T cells), and WT ILC2s either at the time of transplant (BM, T cells + WT ILC2 [day 0]) or 7 days after trans-
plant (BM, T cells + WT ILC2 [day 7]); data represent 2 experiments; n = 12 total in each group. Log-rank (Mantel-Cox) test, ***P < 0.001. (G) Clinical score 
of recipients from Figure 2F. Two-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons, **P < 0.01.
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large clusters of GFP+ ILC2s in Peyer’s patches (PPs) of the colon 
and small bowel (Figure 3A). Evaluation of GFP+ ILC2s by flow 
cytometry confirmed that IL-33–activated cells had a surface 
phenotype similar to that of ex vivo expanded ILC2s (Figure 3B). 
Greater than 90% of donor GFP+ ILCs in the GI tract expressed 
IL-13, while IL-5 expression varied, with more than 40% of ILC2s 
in the GI tract expressing IL-5 (Figure 3C). These findings indicate 
that ILC2s migrate to the GI tract, maintain their phenotype, and 
produce ILC2 signature cytokines.
Infused ILC2s reduce GI tract T cell burden and limit Th1 and 
Th17 induction. We evaluated the effect of the infusion of ILC2s on 
the generation of proinflammatory donor T cells in GVHD target 
organs. Co-infusion of ILC2s reduced the accumulation of donor 
T cells in PP, the colon, and small bowel, as determined by GFP 
intensity (Figure 4A). In addition, there was significantly less GFP 
in tissue homogenates (Figure 4B). To confirm these findings, we 
analyzed T cell infiltration into the lungs, liver, spleen, MLN, and 
colonic LP by flow cytometry (Figure 4C). Recipients of ILC2s had 
a reduction in donor lymphocytes in the LP of the colon (Figure 
4D), with a significant reduction in donor CD8+ T cells (Figure 4E). 
There were significant reductions in the total number of LP CD4+ 
and CD8+ T cells that expressed IFN-γ and CD4+ T cells that gener-
ated IL-17A (Figure 4F). Infusion of ILC2s did not lead to a signifi-
cant difference in the quantity of IFN-γ–producing donor CD4+ or 
CD8+ T cells in other GVHD target organs (Supplemental Figure 5, 
A and B). The decrease in IFN-γ–producing CD4+ and CD8+ T cells 
in the colon was not associated with an increase in T cells generat-
ing IL-10 or an increase in FoxP3-expressing Tregs (Supplemental 
Figure 5, C and D). These data indicate that co-infusion of ILC2s 
is associated with a reduction in the number of proinflammatory 
donor T cells generating IFN-γ and/or IL-17A in the GI tract.
ILC2 suppression of aGVHD is independent of increased Th2 dif-
ferentiation. Conceivably, ILC2s could induce donor Th2 polar-
ization, which would mitigate aGVHD (25). To assess for Th2 
cells after ILC2 infusion, we analyzed IL-4 production by donor 
T cells (Supplemental Figure 5E). We did not observe an increase 
in IL-4–producing donor T cells in recipients of ILC2s in the colon 
(Supplemental Figure 5F). To verify that the mechanisms behind 
ILC2 suppression of aGVHD are independent of the generation of 
Th2 cells, we performed survival studies using T cells from Stat6–/– 
mice (26). Recipients of Stat6–/– T cells alone developed aGVHD, 
with all recipients dying before day 30; however, 80% of recipients 
given Stat6–/– T cells with ILC2s survived long-term, with signifi-
cantly reduced clinical scores by day 20 after BMT (Supplemental 
Figure 5, G and H). The ability of ILC2s to suppress aGVHD does 
not require the generation of donor Th2 cells.
ILC2 infusion enhances LP myeloid cells. We observed an 
increase in donor myeloid cells in the lower GI tract in recipients 
nificant improvement in survival (Figure 2E) and clinical GVHD 
score (Supplemental Figure 4B).
Treatment of aGVHD with ILC2s. While the use of ILC2s to pre-
vent aGVHD would be beneficial, clinically it would be more impact-
ful to use these cells to treat active aGVHD. ILC2s were infused 7 days 
after transplant, a time when donor T cells have initiated inflamma-
tion in GVHD target organs. In B6D2 recipients, infusion of a sin-
gle dose of ILC2s significantly improved survival compared with no 
treatment (Figure 2F). In addition, there was a significant reduction 
in clinical GVHD score in recipients of ILC2s on day 7 (Figure 2G). 
We repeated our day 7 treatment experiments in the complete major 
histocompatibility complex (MHC) mismatch model and found sig-
nificantly improved survival with ILC2 infusion (Supplemental Fig-
ure 4C). These findings indicate that a single infusion of ILC2s can 
significantly improve survival after the onset of GVHD.
ILC2s migrate to the GI tract and produce Th2-inducing cytokines. 
We were interested in determining whether ILC2s migrated to 
GVHD target organs after allo-SCT. For this, we infused B6-GFP+ 
ILC2s into lethally irradiated B6D2 mice. While on day 12 after 
BMT only limited GFP signal was found in the LP, we observed 
Figure 3. ILC2 evaluation in tissues after transplant. (A) Fluorescence 
microscopy of B6-GFP ILC2s in PPs 12 days after BMT; GFP imaging (left) 
and signal intensity (right). Magnification, ×40; exposure, 200 ms. Data 
represent 3 experiments; n = 6 each. (B) Flow cytometry plots of B6-GFP 
ILC2 phenotype in the LP of BMT recipients 12 days after transplant, gated 
first as GFP+. (C) Percentage of B6-GFP ILC2s expressing IL-13 and IL-5; 
average ± SEM. Results represent 3 independent experiments; n = 5 each. 
Sm int, small intestine.
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sion of anti–Gr-1 mAb had no impact on the outcome of recipient 
mice receiving only donor bone marrow cells (Figure 5C). There 
was a similar loss of efficacy of ILC2 infusion after depletion of 
Ly-6C+ cells (Supplemental Figure 6D). Thus, the ability of ILC2s 
to prevent aGVHD is dependent on the presence of Gr-1+ cells.
IL-13 is required for ILC2-induced donor MDSC suppression of 
inflammatory T cells. Next, we performed survival studies to test 
the ability of Il13–/– ILC2s to suppress aGVHD (12). Compared with 
the infusion of BM + T cells alone, there was no significant improve-
ment in median survival for mice receiving BM, T cells, and Il13–/– 
ILC2s (Figure 6A). When compared with mice that received WT 
ILC2 treatment, only 25% of Il13–/– ILC2 recipients survived long-
term as compared with 75% survival when WT ILC2s were given 
(Figure 6A). To further investigate the role of ILC2-derived IL-13 
suppression of aGVHD, we evaluated IFN-γ and IL-17A expres-
sion by donor CD4+ and CD8+ T cells in the colon. The decrease 
in T cells generating IFN-γ and/or IL-17A observed in mice receiv-
ing WT ILC2s was lost after the infusion of Il13–/– ILC2s (Figure 
6B compared with Figure 4F). In addition, Il13–/– ILC2s failed to 
of WT ILC2s (Supplemental Figure 6, A and B). We analyzed 
donor myeloid cells for expression of CD45, CD11b, Gr-1, Ly-6C, 
and Ly-6G, a phenotype that is consistent with MDSCs, which 
have been shown to suppress aGVHD (Figure 5A) (12, 27). We 
found a significant increase in donor MDSCs in the LP of colon 
and small bowel in ILC2-treated recipient mice (Figure 5B). How-
ever, MDSCs were not increased in the lung or liver of recipients of 
ILC2s (Supplemental Figure 6C). To test whether the function of 
ILC2s was dependent on MDSCs, we depleted myeloid cells using 
an anti–Gr-1 mAb in transplanted mice receiving either BM and T 
cells with or without donor ILC2s. Depletion of Gr-1+ cells reduced 
the median survival of control BM and T cell recipients from 25 
to 20 days (Figure 2A compared with Figure 5C). In contrast, 
depletion of Gr-1+ cells completely ablated the beneficial effect 
of ILC2s, with no difference being observed in survival between 
mice receiving donor T cells with anti–Gr-1 antibody and donor 
ILC2s with T cells plus anti–Gr-1 antibody (Figure 5C). The ability 
of anti–Gr-1 mAb to abrogate the beneficial effects of donor ILC2s 
was dependent on the ability of ILC2s to prevent aGVHD, as infu-
Figure 4. Co-transplantation of WT 
ILC2s reduces proinflammatory 
donor T cells numbers in the GI tract. 
Donor T cells were evaluated in the GI 
tract 12 days after transplant using 
GFP+ splenic T cells alone (BM + T 
cells) or GFP+ T cells and WT ILC2s 
(BM, T cells + WT ILC2). (A) Fluores-
cence microscopy of B6-GFP donor T 
cells in PPs; GFP imaging (top row) 
and signal intensity (bottom row). 
Magnification, ×40; exposure, 200 
ms. (B) ELISA quantification of GFP  
in tissue homogenates from BM + 
GFP+ T cells (filled circles) and BM, 
GFP+ T cells + WT ILC2 (open circles) 
normalized to grams of tissue. 
Results represent 3 experiments  
(n = 5 each). Student’s t test with 
Welch’s correction, *P < 0.05,  
***P < 0.001. Donor T cells from BMT 
were evaluated by flow cytometry 
12 days after BMT. (C) Density plots 
and gating scheme for the evalua-
tion of donor T cells and intracellular 
cytokine expression from colon. (D) 
Percentage of donor T cells in the LP 
BM + T cells (filled circles) and BM, T 
cells + WT ILC2 (open circles). (E) The 
total number of CD4+ and CD8+ donor 
T cells in the LP. (F) Total number of 
IFN-γ–producing donor CD4+ and CD8+ 
T cells and the number of donor CD4+ 
T cells producing IL-17A in the LP. Data 
represent 2 independent experiments 
(n = 5). Student’s t test with Welch’s 
correction, *P < 0.05, **P < 0.01.
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enhance donor MDSCs in GVHD target organs (Figure 6C and 
Supplemental Figure 6E). These data indicate a critical role for 
IL-13 production by ILC2 cells to suppress donor T cell production 
of the proinflammatory cytokines IFN-γ and IL-17A.
To evaluate how ILC2s impact the presence of MDSCs, we 
cocultured expanded ILC2s with BM-derived MDSCs (BM-MDSC) 
and quantified MDSCs 72 hours later. BM-MDSCs cultured with 
congenic ILC2s showed significantly enhanced survival compared 
with MDSCs cultured alone, MDSCs cultured in the presence of 
IL-13, and those cultured with IL-7 and IL-33 (Figure 6D). Howev-
er there were a greater number of BM-MDSCs when cultured with 
wild type ILC2s than those cultured with IL-13-deficient ILC2s. To 
evaluate whether ILC2s and MDSCs require cell-to-cell contact, 
we cultured both populations in plates across a semipermeable 
membrane. Enhanced survival of MDSCs by ILC2s was abrogated 
in the absence of cell-to-cell contact (Figure 6D).
ILC2 infusions affect lower GI tract permeability. Previous inves-
tigators have demonstrated a critical role for ILC2s in the main-
tenance of epithelial integrity (13). Six days after BMT, we found 
there was no difference in intestinal permeability when compar-
ing non-irradiated age-matched mice with BMT recipients of BM 
only; BM and T cells; or BM + T cells + WT ILC2s (Figure 7A). On 
days 12 and 20 after transplant, recipients of donor T cells had 
significantly enhanced epithelial permeability compared with 
healthy B6D2 mice as well as recipients of BM only (Figure 7, B 
and C). ILC2-treated mice had significantly improved epithelial 
integrity compared with control mice and showed no statistical 
difference compared with untreated B6D2 or recipients of bone 
marrow alone (Figure 7, B and C). ILC2 infusion is associated with 
improved intestinal barrier function in the setting of reduced low-
er GI tract aGVHD.
Activated ILC2s produce amphiregulin in response to IL-33 
(Supplemental Table 1), which promotes wound healing and 
epithelial barrier repair (15). We evaluated the ability of amphi-
regulin-deficient ILC2s (Areg–/– ILC2) to protect against aGVHD 
mortality. Infusion of Areg–/– ILC2 cells with donor T cells and BM 
led to diminished overall survival compared with recipients of 
WT ILC2 cells (Figure 7D and Figure 2A). However, the kinetics 
of the response differed from that found using Il13–/– ILC2 cells, 
with mortality occurring later after transplant (Figure 7D and Fig-
ure 6A). The infusion of Areg–/– ILC2s failed to increase epithelial 
barrier integrity (Figure 7E). Thus, the generation of amphiregulin 
by ILC2s is critical to the maintenance of the epithelial barrier in 
the GI tract mediated in part by ILC2s.
ILC2 cells do not inhibit the graft-versus-leukemia response. The 
antitumor response mounted by donor T cells is key to the clinical 
Figure 5. Co-transplantation of WT ILC2s increases MDSC numbers in the GI tract. (A) Representative density plots of CD11b+Gr-1+Ly-6C+Ly-6G+ MDSCs 
(gated on donor CD45+cells) 12 days after BMT. (B) Frequencies of MDSCs as a percentage of CD45+ granulocytes in the colon and small (Sm) bowel of BMT 
recipients 12 days after transplant. Results represent 2 independent experiments; bar graphs are average ± SEM. Student’s t test with Welch’s correction, 
*P < 0.05, **P < 0.01. (C) Kaplan-Meier plot showing results of Gr-1 depletion. Lethally irradiated B6D2 mice (950 cGy) received 3.0 × 106 TCD BM (BM only), 
BM plus 4.0 × 106 total splenic T cells (BM + T cells), or BM plus T cells with 4.0 × 106 IL-33–activated ILC2s (BM, T cells + WT ILC2). One group additionally 
received 200 μg anti–Gr-1 (α-Gr-1), with another group receiving isotype control antibody twice weekly beginning 7 days after transplant. Results of 1 repre-
sentative of 2 independent experiments are shown; n = 6 per group.
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efficacy of allo-SCT. We tested the graft-versus-leukemia (GVL) 
response by giving GFP-expressing blast crisis chronic myeloge-
nous leukemia (BC-CML) tumor cells to allogeneic BMT recipi-
ents (28). Recipients of donor T cells had significantly fewer tumor 
cells in the spleen compared with mice receiving T cell–depleted 
(TCD) bone marrow alone, and this effect was independent of the 
infusion of donor ILC2s (Figure 8A).
Comparison of ILC2 with other cell therapy treatments for 
GVHD. Multiple cell populations have been generated in an 
attempt to mitigate the incidence and/or severity of aGVHD. 
Two populations that have recently been evaluated by our 
group are natural Tregs and IL-13 MDSCs (12, 29). To compare 
the function of ILC2s with these other immunosuppressive cell 
populations, we infused Tregs or ILC2s with donor T cells, TCD 
bone marrow, and luciferase-expressing P815 (luc-P815) tumor 
cells. Mice that received BM and luc-P815 without T cells showed 
extensive tumor growth in 
the spleen, MLN, and ingui-
nal lymph nodes. Mice that 
received T cells efficiently 
eliminated tumor cells when 
ILC2s were given (Figure 8A). 
In agreement with a previ-
ous report (30), infusion of 
a 1:1 ratio of Tregs to splenic 
T cells led to suppression of 
aGVHD, but with the loss of 
the graft-versus-tumor effect 
critical for allo-SCT (Figure 
8B). When we evaluated a low-
er dose of Tregs (1:4 ratio), we 
found that the GVL response 
was preserved but that the 
majority of mice succumbed 
to GVHD (Figure 8B). These 
findings indicate that the sur-
vival of B6D2 recipient mice 
transplanted with B6 donor T 
cells and P815 tumor cells is 
significantly improved with 
co-administration of ILC2 
cells compared with a 1:1 or 1:4 
ratio of conventional T cells 
(Tcons) to Tregs (Figure 8C).
When given as treat-
ment, MDSCs fail to sup-
press aGVHD (27). ILC2s and 
MDSCs were given on day 7 
following allo-SCT in mice 
that received BM and splenic 
T cells. When used therapeuti-
cally, MDSCs did not improve 
survival or clinical score com-
pared with mice receiving 
donor T cells alone (Figure 8, 
D and E). However, there was 
a substantial improvement in 
the survival of mice receiving donor ILC2s, with a significant 
reduction in clinical score (Figure 8, D and E). Thus, ILC2s in 
vivo do not inhibit the GVL response found after the infusion of 
Tregs and have significantly improved function to treat aGVHD 
compared with MDSCs.
Human ILC2 expansion. While these findings indicate a crit-
ical role for the administration of donor ILC2s to control lower 
GI tract GVHD, for clinical translation, we needed to expand 
human ILC2s (hILC2s) ex vivo. We isolated CD34+ cord blood 
cells and cultured these cells with IL-33 and IL-2 with/without 
IL-25. Culture with IL-2/IL-33 alone led to 2.5- to 3-log expansion 
of cells; however, the addition of IL-25 allowed for the persistent 
expansion of cells through day 21. Within this bulk population, 
CRTH2+CD161+ lineage-negative hILC2s were found (Figure 8F 
and Supplemental Figure 6F). Thus, human ILC2 cells can be 
expanded ex vivo from CD34+ cord blood progenitors.
Figure 6. Reduced efficacy of ILC2s in the absence of IL-13. B6D2 recipients of B6 TCD BM (BM only), BM plus 
splenic T cells (BM + T cells), or BM plus T cells with cultured Il13–/– ILC2s (BM, T cell + Il13–/– ILC2) were evaluated 
by (A) Kaplan-Meier plot for survival following allo-SCT. Results of 1 representative of 2 combined experiments are 
shown (n = 8 per group in each experiment). WT ILC2 group shown represents one experiments from Figure 2A. 
Immune infiltrates were evaluated in GVHD target organs by flow cytometry 12 days after allo-SCT with or without 
Il13–/– ILC2s. (B) Total number of IFN-γ–producing donor CD4+ and CD8+ T cells and the number of donor CD4+ T 
cells producing IL-17A in the colon LP. Data represent 2 independent experiments; mean ± SEM (n = 5 each). (C) 
Frequencies of CD11b+GR-1+Ly-6C+Ly-6G+ MDSCs (gated on donor CD45+cells) in the colon and small bowel of BMT 
recipients of Il13–/– ILC2s 12 days after transplant. Results represent 2 independent experiments; mean ± SEM. (D) 
BM-MDSCs were cocultured for 72 hours with WT or Il13–/– ILC2s (1:1), or MDSCs alone or with either IL-13 (80 ng/ml) 
or IL-7 and IL-33 (10 ng/ml each). BM-MDSC were cocultured with WT or Il13–/– ILC2s (1:1) in Transwell assays, alone 
or in the presence of IL-13 only. Results represent 2 independent experiments; mean ± SEM. One-way ANOVA with 
Bonferroni’s correction for multiple comparisons, *P < 0.05, ***P < 0.001.
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tion demonstrated poor recovery in patients with the common 
γ-chain deficiency or JAK3 mutation of ILCs, other than ILC1s, 
after stem cell transplantation. Interestingly, the impaired recov-
ery of ILCs after stem cell transplantation was much greater in 
patients receiving non-myeloablative conditioning therapy. The 
impaired recovery of ILCs after transplant was not associated with 
an increased risk of infectious diseases, suggesting that ILCs may 
not be critical in the presence of T and B cells for the control of 
infectious pathogens (33). Our findings suggest that ILCs may only 
be critical in specific uncommon settings, such as assisting in the 
control of the persistent inflammation in the GI tract during severe 
aGVHD. Thus, a substantial number of patients after allogeneic 
SCT may function normally in the absence of a sufficient number 
of ILC2s. A second hypothesis is that precursor ILC2s are present 
in the donor bone marrow population but that cellular plasticity 
and the significant proinflammatory environment after allogeneic 
BMT in the lower GI tract converts these precursor ILC2s to ILC1s 
and/or ILC3s (34–36). Both of these mechanisms could contribute 
to the poor recovery of ILC2s in mice after allogeneic BMT.
ILC2s have been found to impact the presence of alternative-
ly activated macrophages (37). To the best of our knowledge, our 
group is the first to demonstrate a role for ILC2s in the presence of 
MDSCs, which required ILC2 production of IL-13. Previous stud-
ies have shown that IL-13 is capable of activating MDSCs through 
activation of STAT1 and STAT6, and this leads to upregulation of 
arginase and INOS, which are critical to the immunosuppressive 
function of MDSCs (38, 39). Stromal cell production of IL-13 has 
been demonstrated to be important in this process (40). Here we 
Discussion
Steroid-refractory aGVHD of the lower GI tract is the most com-
mon cause of morbidity and mortality in patients who develop 
aGVHD after stem cell transplantation. Here, we demonstrate 
that the administration of donor ILC2s at the time of allo-SCT and 
up to 1 week after transplant significantly improved survival and 
clinical GVHD scores. ILC2s did not abrogate the antitumor GVL 
response, which may not be surprising given their primary func-
tion in the lower GI tract, which is not the site of tumor growth in 
our models or for patients undergoing allo-SCT. Thus, ILC2 infu-
sion provides, what we believe to be, a novel approach to therapy 
for lower GI tract GVHD.
One complication of allo-SCT is the incomplete reconstitu-
tion of immune cells from donor bone marrow. Some cell popula-
tions, such as B-1 lymphocytes, are generated preferentially from 
fetal liver and/or bone marrow and not adult bone marrow cells 
(31). In contrast, ILC2s in the GI tract, which have been shown to 
derive from adult bone marrow precursors, have extremely slow 
reconstitution kinetics after BMT. We find significantly decreased 
numbers of both donor and host ILC2s, with a greater decrease on 
day 28 compared with day 1 after allo-SCT. These findings support 
clinical data regarding the paucity of circulating ILC2s 12 weeks 
after allogeneic stem cell transplantation (32). There are at least 
two potential hypotheses for the impaired recovery of ILC2s from 
donor bone marrow after allogeneic BMT. First, despite their gen-
eration from bone marrow cells during development, precursor 
ILC2s may not be effectively generated from adult bone marrow 
precursor cells. In support of this hypothesis, a recent publica-
Figure 7. ILC2 treatment improves intestinal barrier 
function and does not abrogate the GVL response. 
Quantification of FITC-dextran in the serum of BMT 
recipients (A) 6 days, (B) 12 days, and (C) 20 days after 
transplant. One representative of 2 independent exper-
iments shown; mean ± SEM (n = 5 per group). Statisti-
cal analysis by 1-way ANOVA with Bonferroni’s correc-
tion for multiple comparisons, *P < 0.05, **P < 0.01, 
***P < 0.001. (D) Kaplan-Meier plot of B6D2 recipients 
of B6 TCD BM (BM only), BM plus splenic T cells (BM + 
T cells), or BM plus T cells with cultured Areg–/– ILC2s 
(BM, T cell + Areg–/– ILC2) were evaluated for survival 
following allo-SCT. One representative of 2 experiments 
shown (n = 5 per group in each experiment). WT ILC2 
group shown represents one experiments from Figure 
2A. (E) Quantification of FITC-dextran in the serum of 
BMT recipients 20 days after transplant. One combined 
representative of 2 independent experiments is shown; 
mean ± SEM (n = 5 per group).
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Figure 8. Comparison of ILC2s and other cellular therapies for GVHD. (A) Percentage of GFP+ BC-CML tumor in host 
spleen 21 days after BMT in the B6-into-B6D2 model. Results represent 2 independent experiments (n = 8 each). Analysis 
by Student’s t test with Welch’s correction, ***P < 0.001. (B) IVIS imaging of luc-P815 tumor in B6D2 BMT recipients 15 
days after transplant comparing recipients of BM and luc-P815 cells (BM only); BM with splenic T cells and luc-P815 cells 
(BM + T cells); BM, splenic T cells, Tregs, and luc-P815 cells (BM, T cells + Treg); and BM, splenic T cells, WT ILC2s, and 
luc-P815 cells (BM, T cells + WT ILC2). Results represent 2 independent experiments; n = 5 in each group. (C) Kaplan- 
Meier plot comparing the survival of the allo-SCT recipients described in B. Log-rank (Mantel-Cox) test, **P < 0.01. (D) 
Kaplan-Meier plot comparing the survival of recipients of allo-SCT (B6 into B6D2 model) that received BM alone (BM 
only); BM and splenic T cells (BM + T cells); and those that received BM and splenic T cells at the time of transplant with 
either WT ILC2s (BM, T cells + WT ILC2) or BM-MDSCs (BM, T cells + MDSC) 7 days after BMT. Results represent 2 com-
bined experiments (n = 10 or more per group). Log-rank (Mantel-Cox) test. (E) Clinical scores of recipients from the surviv-
al study in D. **P < 0.01 by 2-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons. (F) 
Expansion of human ILC2s (hILC2) from SR-1–stimulated CD34+ cord blood cells in the indicated cytokines. hILC2s were 
enumerated as CRTH2+CD161–Lin– cells (Supplemental Figure 6F) from days 3 to 21; n = 3.
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In conclusion, we demonstrate that restoration of ILC2s can 
treat GI tract aGVHD; is dependent on the generation of IL-13 and 
amphiregulin by the ILC2s; and unlike Tregs does not impact the 
GVL response. These findings provide a strong preclinical ratio-
nale for testing the infusion of ILC2 cells to treat patients with 
steroid-nonresponsive lower GI tract GVHD.
Methods
Mice. B6, BALB/cJ, B6.129S2 Stat6–/– (termed Stat6–/–), and C57BL/6J × 
DBA/2 F1 (termed B6D2) mice were purchased from The Jackson Lab-
oratory. The generation of enhanced GFP-expressing C57BL/6 mice 
has been described previously (47). C57BL/6 Il13-eGFP and C57BL/6 
Areg–/– mice have been described previously (24, 48). Donor and recip-
ient mice were age-matched males between 8 and 16 weeks.
Isolation and expansion of murine ILC2s and MDSCs. Ten- to 
12-week-old B6 mice were given 0.4 μg recombinant mouse IL-17E/
IL-25 (R&D Systems) by i.p. injection for 4 days. On day 5, cells were 
isolated from the MLN and peritoneum by peritoneal lavage using 
RPMI with 10% fetal bovine serum (complete media). ILC2s were 
isolated by negative selection with a MACs column using biotinylated 
antibodies (anti-CD8α [clone 53-6.7], anti-CD4 [RM 4.4], anti-CD3ε 
[clone 145-2C11], anti-γδTCR [UC7-13DS], anti-TER119 [TER-119], 
anti-B220 [RA3-6B2], anti-CD11b [M1/70], anti-NK1.1 [PK136], eBio-
science; anti-CD11c [N418], anti-CD19 [MB19-1], anti-Ly6G [1A8], and 
anti-CD49b [DX5], BioLegend) and Streptavidin MicroBeads (Miltenyi 
130-048-101). Cells were cultured for 6 days in complete media with 
rIL-7 and rIL-33 (10 ng/ml) (PeproTech), with the media changed every 
2 days. ILC2 activation was evaluated using flow cytometry on day 6 by 
intracellular cytokine staining of IL-5 and IL-13. For BM-MDSCs, freshly 
isolated CD90-depleted BM was plated at 3.0 × 105 cells/ml and incu-
bated 4 days with 250 U/ml recombinant GM-CSF (catalog 315-03) and 
100 ng/ml G-CSF (catalog 250-05) (PeproTech). On day 4, 80 ng/ml 
recombinant IL-13 (catalog 210-13) (PeproTech) was added to the cul-
tures. After 4 days, CD11b+ cells were isolated by magnetic bead sep-
aration using the Miltenyi CD11b+ selection kit (catalog 130-049-601) 
(Miltenyi Biotec). CD11b+ cells were analyzed for expression of Gr-1; 
approximately 96% of the live cells were CD11b+Gr-1+. For ILC2/MDSC 
coculture experiments, ILC2s and MDSCs were plated at a 1:1 ratio at a 
density of 2.0 × 105 cells/ml, in conventional 24-well plates or in 5.0-μm 
filter Transwell plates, with either 10 ng/ml IL-7 and IL-33 or 80 ng/ml 
IL-13 for 3 days before quantitation of live MDSCs by flow cytometry.
RNA sequencing evaluations. RNA was extracted from cultured ILC2s 
using the RNEasy Mini Kit (QIAGEN), and mRNA sequencing (mRNA-
seq) libraries were prepared according to the TruSeq protocol (Illumi-
na). For mRNA-seq, samples were processed as previously described by 
The Cancer Genome Atlas (49). Bases and quality control assessment 
of sequencing were generated by CASAVA 1.8. QC-passed reads were 
aligned to the murine reference genome using MapSplice (50). Aligned 
reads were sorted and indexed using SAMtools (http://www.htslib.
org/), and then translated to transcriptome coordinates and filtered for 
large inserts and zero mapping quality using UBU v1.0 (https://github.
com/mozack/ubu). For the reference transcriptome, UCSC murine 
knownGenes (51) was used, with genes located on nonstandard chro-
mosomes removed. The abundance of transcripts was then estimated 
using an expectation-maximization algorithm implemented in the soft-
ware package RSEM (52) v1.1.13. Estimated counts were normalized to 
the upper quartile (53) prior to comparison of expression across proto-
demonstrate that ILC2s can maintain the viability of MDSCs in 
vitro. This process requires IL-13 generated by ILC2s and cell-to-
cell contact between MDSCs and ILC2s. How this functions in vivo 
is a current focus of our research.
IL-33, which is critical for the generation of ILC2s, is a ligand 
for the IL-33 receptor also termed ST2. Previous work evaluating 
biomarkers as predictors of outcome for patients undergoing allo-
geneic stem cell transplantation has found that elevation of ST2 was 
associated with a lack of therapeutic response for GVHD on day 28 
after transplant and increased mortality 6 months after transplan-
tation (41). In those evaluations, ST2 levels were greater for patients 
undergoing myeloablative compared with reduced-intensity condi-
tioning regimens. These data were confirmed in a study of recipients 
of cord blood transplant (42). We have shown that increased gen-
eration of IL-33 after transplantation is associated with increased 
severity of GVHD in murine models (43), and our group and anoth-
er have found that blocking the interaction of IL-33 with ST2 dimin-
ished aGVHD (44). We hypothesize that the increased levels of ST2 
after transplant are, in part, due to the loss of ILC2s in the GI tract 
that would respond to IL-33. Persistent inflammation in the GI tract 
would lead to increased production of soluble ST2, which would be 
greater after myeloablative conditioning therapy due to the greater 
loss of ILC2s from the increased dose of chemotherapy or irradia-
tion. Our data would suggest that infusion of donor ILC2s, by mark-
edly decreasing the accumulation of IFN-γ– and IL-17–producing T 
cells in the GI tract, diminishes this proinflammatory environment. 
We hypothesize that ST2 levels would significantly decrease after 
ILC2 infusion, which is currently being evaluated.
AREG is a member of the epithelial growth factor receptor 
family and plays a critical role in wound healing after injury (45). 
Basophils, mast cells, CD4+ T cells, eosinophils, and dendritic cells 
in addition to ILC2s can generate AREG. In some specific instanc-
es, FoxP3+ Tregs that express ST2 can generate AREG (46). Our 
data are consistent with a critical role for the production of AREG 
by ILC2s in their function to promote lower GI tract barrier func-
tion. However, we did not determine the relative contribution of 
ILC2s to the generation of AREG in the lower GI tract after trans-
plant. Future work is required to determine whether AREG pro-
duction by these other immune cells (and by non-immune cells) is 
critical to promoting GI tract epithelial integrity after the develop-
ment of acute GVHD.
There are several additional questions that remain to be 
addressed from our findings. The mechanism underlying the 
tissue-specific effects of conditioning therapy on ILC2s found 
in the lung compared with those in the GI tract is not clear. 
This could be related to differences in the microbiota at each 
site. Alterations in the microbiome after conditioning therapy 
could activate ILC2s in the GI tract, leading to enhanced deple-
tion of cycling ILC2s after conditioning therapy. Furthermore, 
there are clear differences in the supporting immune and non- 
immune cells at each site that also could play a role in the cell cycle 
status of ILC2s in the lung compared with the GI tract. Finally, 
how ILC2s and ILC3s interact during aGVHD is not clear. As our 
hypothesis focused on the effects of conditioning therapy on reg-
ulatory immune populations in the GI tract, and since ILC3s in 
the GI tract are not depleted by conditioning therapy, we have not 
performed evaluations focusing on these cells.
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ILCs was performed using the absolute event count of live cells gat-
ed as lineage negative and CD90+. Expression of ICOS or RORγt was 
used to enumerate ILC2s or ILC3s, respectively.
Fluorescence stereomicroscopy and GFP quantification. Organs from 
anesthetized animals were imaged with a Zeiss SteReo Lumar V12 
microscope with GFP bandpass filter (Carl Zeiss MicroImaging Inc.) 
at room temperature. AxioVision (Carl Zeiss) software was used to 
determine GFP intensities. Control and treatment recipient organs 
were imaged using the identical magnification (mag) and exposure 
(exp) times on day +12: PP were imaged at exp 200 ms, mag ×40. 
Organs from recipient animals were homogenized, and absolute GFP 
levels were determined by ELISA (Cell Biolabs, AKR-121). No GFP was 
found in mice receiving sham treatment. Detailed experimental pro-
cedures were conducted as described previously (56).
Cell isolation from GVHD target organs. Spleen, liver, lung, MLN, 
and colon were excised and weighed. LP lymphocytes were isolated 
using the Miltenyi LP dissociation kit (catalog 130-097-410) as per 
the manufacturer’s instructions. Livers and lungs were digested in a 
solution of 1 mg/ml collagenase A (Roche) and 75 U DNase I (Sigma- 
Aldrich) in RPMI 1640/5% newborn calf serum. Digested tissues 
were treated with ACK lysis buffer to remove rbc and were passed 
through 100-μm-pore-size cell strainers. Leukocytes were collected 
at the interface of a 40%/80% Percoll (Sigma-Aldrich) gradient in 
RPMI 1640/5% newborn calf serum. The pelleted cells were washed 
in PBS/2% FBS. Spleens and MLN were teased apart, treated with 
ACK lysis buffer, and washed in PBS/2% FBS.
GVL analysis. BMTs were performed as described, and at the time 
of transplant B6D2 recipients were given 2.5 × 104 GFP+BC-CML or 
luciferase-expressing P815 (luc-P815 tumor cells, ATCC TIB-64) 
(Lentivirus BLIV101PA-1, System Biosciences). Recipients of BC-CML 
tumor were euthanized 21 days after BMT, and splenocytes were eval-
uated for GFP expression by flow cytometry. Tregs were isolated from 
B6 splenocytes using the CD4+CD25+ Regulatory T Cell Isolation Kit 
(130-091-041, Miltenyi Biotec). Recipients of luc-P815 were moni-
tored for survival and tumor infiltration by luciferase imaging on the 
IVIS Kinetic Optical System. Mice received 3 mg D-luciferin (Perkin-
Elmer) 10 minutes prior to imaging. These cell lines were validated 
by MHC typing, GFP or luciferase expression, and growth parameters.
Flow cytometry analysis. ILC2s were evaluated by flow cytometry for 
linage markers (catalog 88-7772) and CD90 (HLS51), ICOS (7E.17G9), 
CD127 (A7R34), T1/ST2 (RMST2-2), Sca-1 (D7), CD44 (IM7), CD25 
(PC61.5), and GITR (DTA-1); and intracellular staining for IL-4 (11B11), 
IL-13 (eBio13A), IL-5 (TRFK5), IFN-γ (XMG1.2), and IL-22 (1H8PWSR). T 
cells were evaluated by surface staining of H2Kd (34-1-2S), CD4 (GK1.5), 
CD8 (clone 53-6.7); and intracellular staining for IFN-γ (XMG1.2), IL-17 
(ebio17B7), IL-4 (11B11), IL-10 (JESS-16E3), and FoxP3 (FJK-16s). For 
analysis of MDSCs, donor cells were stained for the surface markers 
CD45 (30-F11), CD11b (M1/70), CD11c (N418), Gr-1 (RB6-8C5), Ly-6C 
(HK1.4), and Ly-6G (1A8) (eBioscience). Sample acquisition was per-
formed using a BD FACSCanto or BD LSRFortessa (BD Bioscience).
FITC-dextran permeability assay. Intestinal permeability was 
assessed by luminal enteral administration of FITC-dextran 4000 
(Sigma-Aldrich), a non-metabolizable macromolecule that is used 
as a permeability probe. Mice were fasted for 4 hours prior to gavage 
with FITC-dextran (40 mg/100 g body weight). After 4 hours, whole 
blood was collected by cardiac puncture, and FITC-dextran measure-
ments were performed in triplicate by fluorimeter using a PerkinElmer 
cols. Normalized counts were converted to expression rank values for 
comparison with microarray data. RNA-seq raw data files have been 
deposited in the NCBI’s Gene Expression Omnibus (GEO GSE95811).
Comparison of ILC2 mRNA-seq with published microarray data. 
Murine ILC gene signatures and raw microarray data were extracted 
from Robinette et. al. and relevant NCBI GEO datasets (54). Microar-
ray data were processed in R (http://www.R-project.org, R Develop-
ment Core Team, Vienna, Austria) to determine transcript relative 
expression values using the Robust Multichip Average algorithm 
implemented in the oligo package (55). Transcript-level inference of 
relative expression was done by cross-referencing normalized probe 
signal values with the “mogene10sttranscriptcluster” database (Affy-
metrix). Normalized signal values were converted to expression rank 
values for comparison with mRNA-seq data. Spearman rank correla-
tions between gene expression values of ILC-associated genes for 
measured ILC2s (n = 6) and published ILC1s (n = 2, 12 comparisons), 
ILC2s (n = 2, 12 comparisons), and ILC3s (n = 8, 48 comparisons) were 
calculated and used as a statistic. Significance between sample groups 
was evaluated using the Kruskal-Wallis test. Mean rank expression 
values for each gene from each published group were plotted against 
mean rank expression values in the cultured ILC2s. Significance was 
tested using the “cor.test” module in R (method = “spearman”).
Transplantation models. Total T cells were isolated using a Cedar-
lane T cell recovery column kit (Cedarlane Laboratories), followed by 
antibody depletion using PE-conjugated anti–mouse B220 (RA3-B62) 
and anti–mouse CD25 (3C7) antibodies (eBioscience) and magnetic 
bead selection using anti-PE beads (130-0480801, Miltenyi Biotec). 
TCD bone marrow was prepared as described previously (56). The 
day prior to transplantation, recipient mice received either 950 cGy 
(B6D2) or 800 cGy (BALB/c) of total body irradiation. For the B6, 
Il13–/–, Areg–/–, and Stat6–/– into B6D2 or B6 into BALB/c transplants, 
recipients were intravenously injected with either 4 × 106 T cells and 3 
× 106 TCD BM cells, or 5 × 105 total T cells and 5 × 106 TCD BM cells, 
respectively. For ILC2 treatment groups, B6D2 or BALB/c recipients 
also received 4 × 106 or 1 × 106 CD90+ ILC2s, respectively. Recipients 
were monitored twice a week and scored for clinical GVHD symptoms 
(designated “clinical score”) using a semiquantitative scoring system 
as previously described (57, 58); animals were coded for these evalua-
tions. The sample size was chosen for the effect size needed based on 
our previous experience with sample sizes needed to demonstrate a 
significant difference in GVHD scoring between control and treated 
groups. Investigators were blinded to the clinical score and the patho-
logical evaluations. For the scoring evaluation experiments, the inclu-
sion of 9–12 recipients provided a power of 90% to detect a difference 
of 14 days in the median GVHD score of ≥5 with an α error of <0.05 
between control and treated groups. For all experiments, a control 
group received TCD bone marrow alone without additional T cells, 
which controlled for the presence of T cells in the marrow inoculum 
and potential infectious complications during aplasia. MDSC deple-
tion was performed by i.p. injecting recipients twice weekly starting 
on day 7 with 200 μg anti–Gr-1 antibody (RB6-8C5) or anti–Ly-6G 
antibody (Monts-1; BioXCell) until the termination of the experiment.
Evaluation of radiation and chemotherapy sensitivity. B6D2 mice 
received 950 cGy total body irradiation or cyclophosphamide (200 
mg/kg) (Santa Cruz Biotechnology Inc., sc-219703) by i.p. injection. 
Twenty-four hours or 28 days later cells were isolated from the LP, 
MLN, and spleen for evaluation by flow cytometry. Quantitation of 
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EnSpire multimode reader. Dilutions of FITC-dextran in PBS were 
used as a standard curve, and absorption of 50 μl of serum or standard 
was measured at 488 nm.
Expansion of human ILC2s. Isolated CD34+ cells from frozen umbil-
ical cord blood cells (NHLBI Umbilical Cord Blood Unit) were expand-
ed with 50 ng/ml IL-6, Flt3L, SCF, TPO (PeproTech) and 750 nM SR1 
(Sigma-Aldrich) for 15 days. Cells were then cultured in 24-well plates 
at 0.5 × 106/ml with 100 U/ml IL-2 , 50 ng/ml IL-25, and 50 ng/ml 
IL-33 (PeproTech), with RPMI containing 10% human antibody serum 
(Valley Biomedical) and 1% penicillin and streptomycin (Thermo Fish-
er Scientific). Cytokines were replenished every 3 days. On days 5, 
10, 15, 20, and 25, cells were harvested, and flow cytometry was per-
formed. Human ILC2s were characterized as CRTH2+ (BM16) CD161+ 
(HP-3G10) and T cell (OKT3), B cell (HIB19), monocyte (P67.6) lineage- 
negative cells. All antibodies were purchased from eBioscience.
Statistics. Survival differences were evaluated using a Mantel-Cox 
log-rank test. Survival curves were generated using the Kaplan-Mei-
er method. Differences in GVHD clinical and pathology scores were 
determined using 2-way ANOVA, with Bonferroni correction for 
repeated measures of multiple comparisons. Statistical analysis of 
RNA-seq data is described above. Unless otherwise noted in the figure 
legends, all other continuous variables were compared using 2-tailed 
Student’s t test with Welch’s correction. A P value of ≤0.05 was consid-
ered statistically significant.
Study approval. All experiments were performed in accordance 
with protocols approved by the University of North Carolina Institu-
tional Animal Care and Use Committee (application number 14-001).
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